2020-12-23,"GAC MOTOR 2020 Review: Contrarian Upswing, Promising Future"
2020-12-11,"Pomerantz Law Firm Announces the Filing of a Class Action against Kandi Technologies Group, Inc. and Certain Officers  - KNDI"
2020-12-09,Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
2020-12-09,Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
2020-12-02,StrainBrain and Budtenders Association enter into Partnership
2020-11-26,"Is Oncolytics Biotech, Inc. (ONCY) A Good Stock To Buy?"
2020-11-19,Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
2020-11-19,Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
2020-11-17,Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
2020-11-17,Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium
2020-11-11,Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
2020-11-11,Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
2020-11-11,"Oncolytics Biotech, Inc. to Host Earnings Call"
2020-11-09,Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
2020-11-06,Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
2020-11-02,J-Talks Live explores What's Next after the U.S. Election
2020-10-27,Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor
2020-10-19,"Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board"
2020-10-19,"Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board"
2020-10-12,Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
2020-10-07,Oncolytics Biotech® to Participate in BIO Investor Forum Digital
2020-10-07,Oncolytics Biotech® to Participate in BIO Investor Forum Digital
2020-08-26,Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
2020-08-26,Oncolytics Biotech® Doses First Patient in Phase 2 IRENE Study Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
2020-08-10,Oncolytics Biotech® to Participate in Virtual Fireside Chat at the Canaccord Genuity 40th Annual Growth Conference
2020-08-04,Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
2020-06-25,Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
2020-06-25,Oncolytics Biotech® Announces Investigator Sponsored Phase 2 Trial Evaluating Pelareorep-anti-PD-1 Combination Treatment in Triple-Negative Breast Cancer
2020-06-23,Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
2020-06-23,Oncolytics Biotech® Doses First Patient in Phase 2 BRACELET-1 Study Evaluating Pelareorep-Based Combination Therapies in Metastatic Breast Cancer
2020-06-15,Oncolytics Biotech® Establishes New At-The-Market Facility
2020-06-04,Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
2020-06-04,Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting the Induction of Rapid and Persistent Immune Responses With Systemic Pelareorep Treatment
2020-05-29,Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
2020-05-29,Oncolytics Biotech® Presents Clinical Proof-of-Concept Data in Multiple Myeloma at the ASCO Virtual Annual Meeting
2020-05-26,Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
2020-05-26,Oncolytics Biotech® Presents Clinical Data Supporting a Predictive Biomarker of Pelareorep Response in Breast Cancer at the ESMO Breast Cancer Virtual Meeting
2020-05-18,Moderna COVID-19 vaccine data is baby-step in right direction: Expert
2020-05-14,Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
2020-05-14,Oncolytics Biotech® Announces Publication of Abstracts at the 2020 American Society of Clinical Oncology Virtual Annual Meeting
2020-05-13,Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
2020-05-13,Oncolytics Biotech® to Present at the RBC Global Healthcare Conference
2020-05-12,3 Biotech Stocks Under $3 With 200%-Plus Upside Potential
2020-05-08,Oncolytics Biotech® Reports 2020 First Quarter Financial Results and Operational Highlights
2020-05-08,Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
2020-05-05,Stocks surge as more states move to reopen amid coronavirus
2020-05-04,Oncolytics Biotech® to Present Clinical Findings of Pelareorep-Induced Immune Response in Breast Tumors at the ESMO Breast Cancer Virtual Meeting
2020-04-30,Oncolytics Biotech® Announces Changes to Annual General Meeting
2020-04-30,Oncolytics Biotech® Announces Changes to Annual General Meeting
2020-04-17,Oncolytics Biotech® Updates Clinical Development and Operations Activities During the COVID-19 Pandemic
2020-04-15,Have Insiders Been Buying Oncolytics Biotech Inc. (TSE:ONC) Shares?
2020-04-02,Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
2020-04-02,Oncolytics Biotech® Announces Publication of Pelareorep's Clinical Benefit Against KRAS Mutated Colorectal Cancer
2020-03-24,Oncolytics Biotech® Announces Favourable AWARE-1 Safety Update
2020-03-05,Oncolytics Biotech® Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
2020-03-05,"Oncolytics Biotech, Inc. to Host Earnings Call"
2020-02-28,Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
2020-02-28,Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Year End 2019 Financial Results and Operational Highlights
2020-02-11,Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
2020-01-27,Oncolytics Biotech® Announces Statistically Significant Data Identifying CEACAM6 as a Prospective Prognostic Biomarker for Pelareorep in the Treatment of Pancreatic Adenocarcinoma
2020-01-23,"The Zacks Analyst Blog Highlights: Novavax, NanoViricides, Aethlon Medical and Oncolytics Biotech"
2020-01-22,Coronavirus Infects Wall Street: Stocks to Gain & Lose
2020-01-22,Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
2020-01-22,Oncolytics Biotech® Announces Publication of an Abstract for the 2020 Gastrointestinal Cancers Symposium Highlighting CEACAM6 as a Potential Prognostic Biomarker Candidate for Pancreatic Cancer
2020-01-21,Experimental vaccine stocks jump on concerns about new virus in China
2020-01-13,Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
2020-01-13,Oncolytics Biotech® Provides Recap of Key Opinion Leader Call Highlighting Pelareorep's Unique Ability to Activate the Immune System in Late Stage Multiple Myeloma
2020-01-09,Oncolytics Biotech® Announces Key Opinion Leader Call Conducted by ROTH Capital Partners to Discuss Multiple Myeloma
2020-01-06,Will Oncolytics Continue to Surge Higher?
2019-12-12,Oncolytics Biotech(R) Announces Abstract Outlining Potential New Biomarker to be Presented at the 2020 Gastrointestinal Cancers Symposium
2019-12-09,Oncolytics Biotech(R) Announces Positive Multiple Myeloma Data Presented at the 61st Annual Meeting & Exposition of the American Society of Hematology
2019-12-06,Oncolytics Biotech(R) Regains Compliance with Nasdaq Minimum Bid Price Requirement
2019-12-03,Oncolytics Biotech(R) Presents Clinical Data at the Fifth Annual Oncolytic Virotherapy Conference Highlighting Definitive Evidence of Systemic Delivery and Replication of Pelareorep in Tumor Tissue
2019-11-25,Companies Like Oncolytics Biotech (TSE:ONC) Can Be Considered Quite Risky
2019-11-12,Oncolytics Biotech(R) Reports 2019 Third Quarter Financial Results and Operational Highlights
2019-11-12,Oncolytics Biotech(R) Announces Exercise of Warrants
2019-11-08,Oncolytics Biotech(R) Announces AWARE-1 Data Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
2019-11-07,Oncolytics Biotech(R) Announces Abstract Published for the 61st Annual Meeting & Exposition of the American Society of Hematology
2019-11-06,Oncolytics Biotech(R) Announces Publication of Positive REO 024 Study Results for Pelareorep in Combination with Keytruda(R) in Patients with Advanced Pancreatic Adenocarcinoma
2019-11-05,Oncolytics Biotech(R) to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights
2019-10-31,Oncolytics Biotech(R) Provides Update on Partner Adlai Nortyes Clinical Progress
2019-10-22,Oncolytics Biotech(R) and PrECOG Announce Collaboration for BRACELET-1 (PrE0113) Study in Metastatic Breast Cancer
2019-10-17,Oncolytics Biotech(R) Appoints Experienced Financial and Strategic Leader Leonard Kruimer to Board of Directors
2019-10-15,Oncolytics Biotech(R) Presents Clinical Data Highlighting the Effectiveness of Intravenous Delivery to and Replication of Pelareorep in Tumors
2019-10-01,Oncolytics Biotech(R) Announces Abstract to be Presented at the 34th Annual Meeting of the Society for Immunotherapy of Cancer
2019-09-30,"Oncolytics Biotech CEO, Matt Coffey, Honored with Scientific Achievement and Innovation Award by BioAlberta"
2019-09-25,Oncolytics Biotech(R) Announces Upcoming Presentation at the 12th Annual International Oncolytics Virus Conference
2019-09-23,Oncolytics Biotech(R) Announces Upcoming Conference Participation
2019-09-20,Oncolytics Biotech(R) Receives Nasdaq Notification Letter
2019-09-17,Oncolytics Biotech(R) to Present at the Ladenburg Thalmann Healthcare Conference
2019-09-05,Oncolytics Biotech(R) to Present at the H.C. Wainwright 21st Annual Global Investment Conference
2019-09-04,Oncolytics Biotech(R) to Host Corporate Update Call to Discuss Recent Highlights and Expanded Catalysts and Milestones
2019-08-16,Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants
2019-08-15,"The Daily Biotech Pulse: Mallinkckrodt's Terlipressin, Deciphera Offering, Sellas Reboots On Earnings"
2019-08-14,CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
2019-08-14,Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
2019-08-13,Oncolytics Biotech(R) Announces Public Offering of Common Shares and Warrants
2019-08-13,Oncolytics Biotech(R) Reports 2019 Second Quarter Financial Results and Operational Highlights
2019-07-23,Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)
2019-06-05,Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA
